Localized Therapeutics for the Treatment of Gastrointestinal Disorders
| Status: | Completed |
|---|---|
| Conditions: | Gastrointestinal, Digestive Disease |
| Therapuetic Areas: | Gastroenterology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 8/18/2018 |
| Start Date: | January 30, 2015 |
| End Date: | September 28, 2015 |
The purpose of this study is to determine the patient preference for a biocompatible
thermosensitive solution-gel versus water or saline (liquid) enema. The thermosensitive
solution-gel is comprised of poloxamer, an inactive compound that is designated as GRAS
(generally recognized as safe) by FDA. It could subsequently be used as a medium for drug
delivery. The poloxamer (gel) is administered to study participants in order to assess
preference and proximal distribution.
thermosensitive solution-gel versus water or saline (liquid) enema. The thermosensitive
solution-gel is comprised of poloxamer, an inactive compound that is designated as GRAS
(generally recognized as safe) by FDA. It could subsequently be used as a medium for drug
delivery. The poloxamer (gel) is administered to study participants in order to assess
preference and proximal distribution.
Inclusion Criteria:
- Generally healthy
- Age 18 to 70 years old
- Non-pregnant
Exclusion Criteria:
- GI complaints
- Pregnancy
- Patients with previous colonic surgery or current bowel injury or obstruction
- Allergies to contrast
We found this trial at
1
site
Stanford University Stanford University, located between San Francisco and San Jose in the heart of...
Click here to add this to my saved trials
